NL-OMON41612已完成不适用
Chloroquine as an anti-autophagic radiosensitizing drug in stage I-III small cell lung cancer (SCLC) patients: A phase I trial. - Chloroquine I-III
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •. Histologically or cytologically confirmed ``stage I-III`` ie stage T0-4 N0-3 M0 small cell lung cancer, excluding malignant pleural/pericardial effusion.
- •. WHO performance status 0-2
- •. Absolute neutrophil count at least 1800/µl and platelets at least 100000/µl and hemoglobin at least 6.2 mmol/l.
- •. Adequate renal function: calculated creatinine clearance at least 60 ml/min
- •. Adequate hepatic function: Total bilirubin * 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase * 2.5 x ULN for the institution (in case of liver metastases * 5 x ULN for the institution)
- •. No previous platinum chemotherapy or topo-isomerase-inhibitors for SCLC.
- •. Lung function: FEV1 at least 30 % and DLCO at least 30 % of the age predicted value
- •. No history of prior chest radiotherapy
- •. Life expectancy more than 6 months
- •. Willing and able to comply with the study prescriptions
- •. 18 years or older
- •. Not pregnant or breast feeding and willing to take adequate contraceptive measures during the study
- •. Ability to give and having given written informed consent before patient registration
- •. No mixed pathology, e.g. non-small cell plus small cell cancer
- •* No recent (< 3 months) severe cardiac disease (NYHA class >1) (congestive heart failure, infarction)
- •. No history of cardiac arrythmia (multifocal premature ventricular contractions, uncontrolled atrial fibrillation, bigeminy, trigeminy, ventricular tachycardia) which is symptomatic and requiring treatment (CTC AE 3.0), or asymptomatic sustained ventricular tachycardia. Asymptomatic atrial fibrillation controlled on medication is allowed.;. No cardiac conduction disturbances or medication potentially causing them:;- QTc interval prolongation with other medications that required discontinuation of the treatment
- •- Congenital long QT-syndrome or unexplained sudden death of first degree relative under 40 years of age
- •- QT interval > 480 msec (note: when this is the case on screening ECG, the ECG may be repeated twice. If the average QT-interval of these 3 measurements remains below 480 msec, patient is eligible)
- •- Patients on medication potentially prolongating the QT-interval are excluded if the QT-interval is > 460 msec (Appendix, table 2).
- •- Medication that might cause QT-prolongation or Torsades de pointes tachycardia is not allowed (Appendix, Table 1). Drugs with a risk of prolongating the QT-interval that cannot be discontinued are allowed, however, under close monitoring by the treating phtysician (Appendix, table 2).
- •- complete left bundle branch block;* No uncontrolled infectious disease
- •. No other active malignancy
- •. No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy) in previous 4 weeks
- •. No treatment with investigational drugs in 4 weeks prior to or during this study
- •. No chronic systemic immune therapy
- •. No known G6PD deficiency
- •. Patients must not have psoriasis or porphyria.
- •. No known hypersensitivity to 4-aminoquinoline compound.
- •. Patients must not have retinal or visual field changes from prior 4-aminoquinoline compound use.
- •. No known prior hypersensitivity to cisplatin, etoposide or chloroquine or any of their components.
排除标准
- •The opposite of the inclusion criteria
研究者
相似试验
已完成
不适用
Chloroquine as an anti-autophagic chemosensitizing drug in stage IV small cell lung cancer (SCLC) patients: A phase I trial.10029107small cell lung cancerNL-OMON37990MAASTRO clinic24
终止
1 期
Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung CancerSmall Cell Lung CancerNCT01575782Maastricht Radiation Oncology5
进行中（未招募）
不适用
Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial. - chloroquine in SCLCEUCTR2009-014772-22-NLMAASTRO Clinic
进行中（未招募）
不适用
Treatment with hydroxychloroquine and erlotinib in patients with non-small-cell lung cancerPatients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC)• with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR• who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïve.EUCTR2011-004903-20-NL136
已完成
2 期
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trialAdvanced stage NSCLCMetastatic NSCLC10038666NL-OMON37508Vrije Universiteit Medisch Centrum136